The risk of melanoma with rasagiline compared with other antiparkinsonian medications: A retrospective cohort study in the United States medicare database.
Catherine B JohannesCatherine W SaltusJames A KayeBrian CalingaertSigal KaplanMark Forrest GordonElizabeth B AndrewsPublished in: Pharmacoepidemiology and drug safety (2022)
A small increased incidence of melanoma with exposure to rasagiline compared with other APDs was observed. Although the pattern with dose and duration is consistent with a hypothesized biologic effect, the increased skin cancer surveillance among rasagiline users suggests surveillance bias as a contributing explanation for the observed results.